MD Anderson Faculty Members Published in New England Journal
On February 20, 2014 the New England Journal of Medicine; Vol. 370, No. 8 published the article “A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma” which was written in collaboration by faculty members of MD Anderson Cancer Center.
Please join the Brain and Spine Center and the Department of Neuro-Oncology in congratulating Mark Gilbert, MD, Terri Armstrong, PhD, Jeffrey Wefel, PhD, Ivo Tremont, MD, Paul Brown, MD, Erik Sulman, MD, and Kenneth Aldape, MD (as well as the rest of the team) for this accomplishment.
The Department of Neuro-Oncology provides state-of-the-art treatment for patients with cancers of the brain and nervous system. Physicians in the department also provide expert care for patients that endure neurologic complications from cancer or cancer therapies. The department cares for more than 500 new patients with brain tumors each year.
The neuro-oncology team of skilled and experienced physicians participates in a multidisciplinary approach to cancer care — neurologists treat central and peripheral nervous system conditions that may affect cancer patients, while neuropsychologists diagnose and treat cognitive and behavioral effects of cancer, or help patients learn ways to minimize cancer's impact on their quality of life. In addition, physicians in the department work with neurosurgeons, radiation oncologists, neuropathologists and neuroradiologists to plan a course of treatment that is unique and comprehensive for each patient. The physicians treat patients that are battling central nervous system tumors, including gliomas (glioblastoma multiforme, astrocytoma, brainstem glioma, ependymoma, oligodendroglioma), meningioma, vestibular schwannoma, central nervous system lymphoma, metastatic disease to the brain and spine, or primary spinal cord tumors.
Physicians in the department of Neuro-Oncology also specialize in genetic disorders. Neurofibromatosis is a genetic disorder that causes tumors to grow in the nervous system. The Neurofibromatosis Working Group provides exceptional care and treatment for patients with the disorder. It also works to translate laboratory advances into improved treatments for these patients. The group is a collaborative effort that includes Neuro-Oncology, Neurosurgery and Investigational Cancer Therapeutics.
Central to the department's mission is the discovery of new therapies for malignant and benign tumors and genetic disorders through clinical and laboratory research. In the laboratory, we test new therapeutic agents and approaches to gene therapy to target and kill cancer cells, or to disrupt the signaling pathways that control tumor growth. The Department of Neuro-Oncology is developing drug combination strategies that can overcome the tumor cell's ability to develop resistance to a single drug. Another important goal of the program is to develop and fund translational research so that therapies developed in the laboratory can be quickly brought to the clinical setting.
Treatment at MD Anderson
Diseases We Treat
News & Features
Find Clinical Trials
Clinical trials are research studies that test new cancer drugs, diagnostic procedures and therapies on humans.